Overview

A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)

Status:
Recruiting
Trial end date:
2025-05-21
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the study is to evaluate the efficacy of rilematovir compared to placebo treatment with respect to the clinical outcome on the RSV Recovery Scale (RRS).
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Janssen Research & Development, LLC
Criteria
Inclusion criteria:

- The participant weighs within greater than or equal to (>=) 2.4 kilograms (kg) and
less than or equal to (<=) 24.6 kg

- Each participant's parent(s) (preferably both if available or as per local
requirements) or their legally acceptable representative(s) has/have signed an
informed consent form (ICF) indicating that (s)he understands the purpose of, and
procedures required for, the study; is willing for their child to participate in the
study; with regards to the concomitant medication, the lifestyle consideration and
study procedures and assessments to be performed by the parent(s)/caregiver(s) as well
as those by the investigator/study site personnel

- The participant has an acute respiratory illness with at least 1 of the signs/symptoms
within 24 hours prior to start of screening and at screening, as evaluated by the
investigator in Upper respiratory tract infection: nasal congestion or rhinorrhea; and
Lower respiratory tract infection: increased respiratory effort (as evidenced by
subcostal, intercostal or tracheosternal retractions, grunting, head bobbing, nasal
flaring, or tachypnea), wheezing, cough, cyanosis, or apnea; and systemic/general:
feeding difficulties (defined as <75 percent [%] intake of normal food amounts);
dehydration; fever; disturbed sleep, or disturbed activity level
(irritable/restless/agitated/less responsive). Cough or wheezing cannot be the only
LRTI sign/symptom present, that is, at least one other LRTI sign/symptom needs to be
present for eligibility

- The time of onset of RSV signs/symptoms to the anticipated time of randomization must
be less than or equal to (<=) 3 days. Onset of signs/symptoms is defined as the time
of the day (or part of the day if time of the day cannot be specified) the
parent(s)/caregiver(s) became aware of the first sign and/or symptom consistent with
respiratory or systemic/general manifestation of signs/symptoms of RSV infection. The
time of sign/symptom onset has to be assessed as accurately as possible

- Participants are otherwise healthy or have (a) risk factor(s) for severe RSV disease

Exclusion criteria:

- The participant has had either confirmed severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) infection (test positive) during the four weeks prior to
randomization, or close contact with a person with COVID-19 (test confirmed or
suspected SARS CoV-2 infection) within 14 days prior to randomization

- Confirmed QT interval corrected for heart rate according to Fridericia's formula
(QTcF) interval greater than (>) 450 milliseconds (msec) per the machine read
parameter result at screening. Presence of an abnormal QTcF interval should be
confirmed by repeat electrocardiogram (ECG) recording during screening

- Known personal or family history of Long QT Syndrome or sudden cardiac death

- Presence of repetitive ventricular premature contractions (>10/minutes [min]), second-
or third-degree heart block, or complete or incomplete left bundle branch block, or
complete right bundle branch block per the machine read ECG result at screening.
Presence of any of the above abnormalities should be confirmed by repeat ECG recording
during screening